Cholesteryl linoleate
Based on 1 publication(s) in Google Scholar
Cholesteryl linoleate is a cholesteryl ester with antibacterial activity that is present in low-density lipoprotein (LDL) particles, human nasal fluid, and respiratory epithelial secretions. Cholesteryl linoleate is oxidized by 12/15-lipoxygenase in macrophages and participates in selective uptake and efflux via LDL receptor-related protein. Cholesteryl linoleate does not induce endothelial adhesion molecule expression, nor does it induce monocyte binding to endothelial cells. Cholesteryl linoleate liposomal formulations inhibit the growth of multiple bacteria at physiological nasal fluid concentrations and act synergistically with antimicrobial peptides. Cholesteryl linoleate is useful for research related to atherosclerosis and bacterial infections.
For research use only. We do not sell to patients.
- Purity : 99.45%
- CAS No.: 604-33-1
- Formula: C45H76O2
- Molecular Weight:649.10
-
Storage:Powder -20°C, 3 years ; In solvent -80°C, 6 months , -20°C, 1 month
Publications Citing Use of MedChemExpress (MCE) Cholesteryl linoleate
MoreAll Endogenous Metabolite Isoforms
More
Biological Activity
Description
IC50 & Target
[1]|
Human Endogenous Metabolite |
In Vitro
Cholesteryl linoleate (5-40 μg/mL; 4 h) does not induce the adhesion of monocyte-like U937 cells, peripheral blood mononuclear cells, neutrophils, or neutrophil-like HL-60 cells to human umbilical vein endothelial cells[1].
Cholesteryl linoleate (4 h) does not upregulate the expression of E-selectin, ICAM-1, or VCAM-1 on the surface of human umbilical vein endothelial cells[1].
Cholesteryl linoleate in LDL is oxidized by J774A.1 cells expressing 12/15-LOX, primarily yielding 13S-hydroxycholesteryl linoleate, whereas mock-transfected cells lacking 12/15-LOX activity show no such oxidative effect[2].
Cholesteryl linoleate is oxidized in LDL by 12/15-LOX-expressing J774A.1 cells, which requires LRP but not the LDL receptor[2].
Cholesteryl linoleate in LDL is selectively taken up by mouse peritoneal macrophages and 12/15-LOX-expressing J774A.1 cells via LRP-mediated uptake[2].
Cholesteryl linoleate is a major cholesteryl ester present in normal human nasal fluid, with an average concentration in the low μg/mL range[3].
Cholesteryl linoleate (2-64 μg/mL; 16 h) liposomes inhibit the growth of Pseudomonas aeruginosa in a dose-dependent manner[3].
Cholesteryl linoleate (64 μg/mL; 3 h) liposomes exhibit bactericidal activity against Pseudomonas aeruginosa[3].
Cholesteryl linoleate (64 μg/mL; 16 h) liposomes inhibit the growth of Staphylococcus epidermidis, Enterococcus faecalis, and Enterobacter cloacae[3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:human umbilical vein endothelial cells (HUVECs)
-
Concentration:5, 10, 20 and 40 μg/mL
-
Incubation Time:4 h
-
Result:Did not induce the expression of E-selectin, ICAM-1, or VCAM-1 on the surface of HUVECs at concentrations effective for oxidized cholesteryl linoleate to induce monocyte-endothelial interactions.
Chemical Information
-
CAS No. 604-33-1
-
Appearance Solid
-
Molecular Weight 649.10
-
Formula C45H76O2
-
Color White to off-white
-
SMILES
CC(C)CCC[C@@H](C)[C@H]1CC[C@@]2([H])[C@]3([H])CC=C4C[C@@H](OC(CCCCCCC/C=C\C/C=C\CCCCC)=O)CC[C@]4(C)[C@@]3([H])CC[C@]12C
-
Structure Classification
-
Initial Source
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Powder -20°C 3 years In solvent -80°C 6 months -20°C 1 month
Publications (1)
-
Journal Impact Factor
-
Most Recent
Solvent & Solubility
In Vitro:
Ethanol : 2.5 mg/mL (3.85 mM; ultrasonic and warming and heat to 60°C)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
In Vivo:
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.5 mg/mL (3.85 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.5 mg/mL (3.85 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
In Vivo Dissolution Calculator
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Working solution concentration: 0.22 mg/mL
Purity & Documentation
-
Data Sheet (279 KB)
-
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Korean - KR (252 KB)
- Portuguese - PT (252 KB)
-
Handling Instructions (2659 KB)
References
[1]. Huber J, et al. Oxidized cholesteryl linoleates stimulate endothelial cells to bind monocytes via the extracellular signal-regulated kinase 1/2 pathway. Arteriosclerosis, thrombosis, and vascular biology. 2002 Apr 01;22(4):581-6. [Content Brief]
[3]. Do TQ, et al. Lipids including cholesteryl linoleate and cholesteryl arachidonate contribute to the inherent antibacterial activity of human nasal fluid. J Immunol. 2008 Sep 15;181(6):4177-87. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| Ethanol | 1 mM | 1.5406 mL | 7.7030 mL | 15.4059 mL | 38.5149 mL |
Keywords
- Cholesteryl linoleate
- 604-33-1
- Endogenous Metabolite
- Bacterial
- human umbilical vein endothelial cells
- 12/15-lipoxygenase
- U937 cells
- macrophages
- respiratory epithelial secretions
- Pseudomonas aeruginosa
- atherosclerosis
- low-density lipoprotein particles
- LDL receptor-related protein
- human nasal fluid
- Inhibitor
- inhibitor
- inhibit